Nanjing Housheng Pharmaceutical

Nanjing Housheng Pharmaceutical is a China-based clinical-stage biopharmaceutical company dedicated to the research and development of innovative small molecule therapeutics. The company focuses on high-prevalence diseases with significant unmet needs, particularly in the fields of metabolic disorders and oncology. Its flagship program, HS-101, is a highly selective URAT1 inhibitor currently in Phase 3 clinical trials for the treatment of hyperuricemia and gout. Beyond its lead program, Nanjing Housheng is advancing a robust pipeline of candidates targeting various metabolic and inflammatory pathways. The company operates out of Nanjing and has secured significant venture capital funding to support its clinical programs. Nanjing Housheng leverages its internal R&D platform to discover novel chemical entities with improved safety and efficacy profiles.